Progesterone Receptor Antagonists – A Novel Treatment for Severe Hyponatremia from the Endocrine Paraneoplastic Syndrome

Jerome H. Check (Cooper Medical School of Rowan University, Dept. OB/GYN, Div. Reproductive Endocrinology & Infertility, Camden, NJ, USA;Cooper Institute for Reproductive Hormonal Disorders, P.C., MT. Laurel, NJ, USA)
Diane L. Check (Cooper Institute for Reproductive Hormonal Disorders, P.C., MT. Laurel, NJ, USA)
Michael P. Dougherty (Augusta University, Augusta, Georgia, USA)

Abstract


Hyponatremia related to ectopic secretion of cancer cells of argininevasopressin (AVP) or atrial natriuretic peptide (ANP) is most commonlycaused by small cell lung cancer. The ideal treatment would be one thatnot only corrects the hyponatremia, especially if it is life threatening, butat the same time causes regression of the cancer, and thus improves bothquality and length of life. As one is waiting for chemotherapy, surgery,or radiotherapy to decrease the cancer burden, tolvaptan has been usedto correct the hyponatremia to improve symptoms or prevent death.Mifepristone, a progesterone receptor modulator/antagonist has been usedto treat various cancers. The oral 200mg tablet was given to an 80-year-oldwoman who developed sudden extensive lung cancer with a serum sodiumof 118 mmol/L. She refused chemotherapy but agreed to take mifepristone.The hyponatremia was completely corrected (145 mmol/L) within onemonth of treatment. She was in complete remission for 5 years and diednot from lung cancer, but an acute myocardial infarction. Mifepristonemay serve the purpose to not only quickly correct hyponatremia when itis related to an endocrine paraneoplastic syndrome, but also to provideimproved quality and length of life.

Keywords


Arginine vasopressor (AVN);Atrial natriuretic peptide (ANP);Lung cancer;Syndrome of inappropriate anti-diuretic;hormone (SIADH);Mifepristone

Full Text:

PDF

References


[1] Mazzone PJ, Arroliga AC. Endocrine paraneoplastic syndromes in lung cancer. Curr Opin Pulm Med. 2003 Jul;9(4):313-20.

[2] Efthymiou C, Spyratos D, Kontakiotis T. Endocrine paraneoplastic syndromes in lung cancer. Hormones (Athens). 2018 Sep;17(3):351-358.

[3] Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med. 1957 Oct;23(4):529-42.

[4] Vorherr H, Massry SG, Utiger RD, Kleeman CR. Antidiuretic principle in malignant tumor extracts from patients with inappropriate ADH syndrome. J Clin Endocrinol Metab. 1968 Feb;28(2):162-8.

[5] Amatruda TT Jr, Mulrow PJ, Gallagher JC, Sawyer WH. Carcinoma of the lung with inappropriate antidiuresis. Demonstration of antidiuretic-hormone like-hormone activity in tumor extract. N Engl J 1963269:544-9.

[6] List AF, Hainsworth JD, Davis BW, Hande KR, Greco FA, Johnson DH. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol. 1986 Aug;4(8):1191-8.

[7] Lokich JJ. The frequency and clinical biology of the ectopic hormone syndromes of small cell carcinoma. Cancer. 1982 Nov 15;50(10):2111-4.

[8] Monsieur I, Meysman M, Noppen M, de Greve J, Delhove O, Velckeniers B, Jacobvitz D, Vincken W. Non-small-cell lung cancer with multiple paraneoplastic syndromes. Eur Respir J. 1995 Jul;8(7):1231-4.

[9] Tho LM, Ferry DR. Is the paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in lung cancer always attributable to the small cell variety? Postgrad Med J. 2005 Nov;81(961):e17.

[10] Kamoi K, Ebe T, Hasegawa A, Sato F, Takato H, Iwamoto H, Kaneko H, Ishibashi M, Yamaji T. Hyponatremia in small cell lung cancer. Mechanisms not involving inappropriate ADH secretion. Cancer. 1987 Sep 1;60(5):1089-93.

[11] Cogan E, Debiève MF, Philipart I, Pepersack T, Abramow M. High plasma levels of atrial natriuretic factor in SIADH. N Engl J Med. 1986 May 8;314(19):1258-9.

[12] Donckier JE, Meunier HT, Ketelslegers JM, Lambert AE. Atrial natriuretic peptide and the syndrome of inappropriate secretion of antidiuretic hormone. Ann Intern Med. 1986 Nov;105(5):795-6.

[13] Hansen O, Sørensen P, Hansen KH. The occurrence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer. 2010 Apr;68(1):111-4.

[14] Yeung SC, Habra MA, Thosani SN. Lung cancer-induced paraneoplastic syndromes. Curr Opin Pulm Med. 2011 Jul;17(4):260-8.

[15] Hainsworth JD, Workman R, Greco FA. Management of the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer. Cancer. 1983 Jan 1;51(1):161-5.

[16] Saintigny P, Chouahnia K, Cohen R, Pailler MC, Brechot JM, Morere JF, Breau JL. Tumor lysis associated with sudden onset of syndrome of inappropriate antidiuretic hormone secretion. Clin Lung Cancer. 2007 Jan;8(4):282-4.

[17] Check DL, Check JH: Significant palliative benefits of single agent mifepristone for advanced lung cancer that previously failed standard therapy. Med Clin Sci 2019;1(2):1-5.

[18] Check JH, Check D, Poretta T: Mifepristone extends both length and quality of life in a patient with advanced non-small cell lung cancer that has progressed despite chemotherapy and a check-point inhibitor. Anticancer Res 2019;39:1923-1926.

[19] Check DL, Check JH, Poretta T, Aikins J, Wilson C: Prolonged high-quality life in patients with nonsmall cell lung cancer treated with mifepristone who advanced despite osimertinib. Cancer Sci Res 2020;3(2):1-5.

[20] Check JH, Dix E, Cohen R, Check D, Wilson C: Efficacy of the progesterone receptor antagonist mifepristone for palliative therapy of patients with a variety of advanced cancer types. Anticancer Res 2010;30:623-628.

[21] Check JH, Dix E, Sansoucie L, Check D: Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon – case report. Anticancer Res 2009 May;29(5):1611-1613.

[22] Check JH, Wilson C, Cohen R, Sarumi M: Evidence that mifepristone, a progesterone receptor antagonist can cross the blood brain barrier and provide palliative benefits for glioblastoma multiforme grade IV. Anticancer Res 2014;34:2385-2388.

[23] Check DL, Check JH, Poretta T: Conservative laparoscopic surgery plus mifepristone for treating multifocal renal cell carcinoma. Cancer Sci Res 2020;3(2):1-4.

[24] Check JH, Check D, Srivastava MD, Poretta T, Aikins JK: Treatment with mifepristone allows a patient with end-stage pancreatic cancer in hospice on a morphine drip to restore a decent quality of life. Anticancer Res 2020;40:6997-7001.

[25] Check JH, Check D, Poretta T, Wilson C: Palliative benefits of oral mifepristone for the treatment of metastatic fibroblastic osteosarcoma. Anticancer Res 2021;41:2111-2115.

[26] Check JH, Check D: Mifepristone may be the best single pharmaceutical agent for treatment of a variety of advanced cancers. Cancer Sci Res 2021;4:1-6.

[27] Check JH, Nazari P, Goldberg J, Yuen W, Angotti D: A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion. Med Hypoth 57:337-343, 2001.

[28] Check JH, Dix E, Sansoucie L: Support for the hypothesis that successful immunotherapy of various cancers can be achieved by inhibiting a progesterone associated immunomodulatory protein. Med Hypoth 2009;72:87-90.

[29] Check JH, Cohen R: The role of progesterone and the progesterone receptor in human reproduction and cancer. Exp Rev Endocrinol Metab 2013;8:469-484.

[30] Check JH: The role of progesterone and the progesterone receptor in cancer. Expert Review Endo Metab 2017;12:187-197.

[31] Check JH, Check D: Therapy aimed to suppress the production of the immunosuppressive protein progesterone induced blocking factor (PIBF) may provide palliation and/or increased longevity for patients with a variety of different advanced cancers – A review. Anticancer Res 2019;39:3365-3372.

[32] Gralla RJ, Ahmad F, Blais JD, Chiodo J 3rd, Zhou W, Glaser LA, Czerwiec FS. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials. Cancer Med. 2017 Apr;6(4):723-729.

[33] Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006 Nov 16;355(20):2099-112.

[34] Schrier RW. Vasopressin and aquaporin 2 in clinical disorders of water homeostasis. Semin Nephrol. 2008 May;28(3):289-96.

[35] Petereit C, Zaba O, Teber I, Lüders H, Grohé C. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm Med. 2013 Aug 29;13:55.



DOI: https://doi.org/10.30564/jer.v3i2.3611

Refbacks

  • There are currently no refbacks.
Copyright © 2021 JEROME H. CHECK


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.